Kurome Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Kurome Therapeutics, Inc. - overview
Established
2019
Location
Cincinnati, OH, US
Primary Industry
Biotechnology
About
Based in Ohio, US, and founded in 2019, Kurome Therapeutics operates as a pre-clinical stage company that focuses on developing targeted kinase inhibitors for patients with hematological cancers. The company was co-founded by Jan Rosenbaum and John Rice and is backed by Series A investors Affinity Asset Advisors, CincyTech, and Medicxi Ventures in June 2021. Kurome Therapeutics develops a series of IRAK-4 (interleukin-1 receptor-associated kinase 4) and panFLT3 inhibitors to target adaptive resistance mechanisms in cancer cells. The company also helps to improve the outcome of patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Kurome Therapeutics plans to use the funding to support the pre-clinical advancement of dual IRAK1/4 and panFLT3 inhibitors.
Current Investors
CincyTech, Medicxi, Affinity Asset Advisors
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.kurometherapeutics.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Kurome Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.